About Oxford Immunotec
Oxford Immunotec’s T-SPOT.TB test and other leading products and services are now part of Revvity’s portfolio. In May, Revvity launched as a science-based solutions company focused on developing technologies and solutions across disease pathways to help solve the world’s greatest health challenges. Revvity was previously affiliated with PerkinElmer, Inc. which purchased Oxford Immunotec in 2021.
Oxford Immunotec is a global, high-growth diagnostics company. We bring energy and invention to a world in need of diagnostic truth. We are uniquely placed as the only company in the world offering regulated ELISPOT assays for T cell measurement, with approval around the globe. Our leading product, the T-SPOT.TB test, is used for diagnosing infection with Tuberculosis, the world’s largest cause of death from infectious disease. The Company has over 18 years’ experience as a manufacturer of IVD tests, operating under a fully audited Quality Management System, ensuring rigorous batch control. The company has manufactured in excess of 20 million clinical T cell tests for TB infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States (where it has received pre-market approval from the Food and Drug Administration), Europe (where it has obtained a CE mark), as well as Japan and China. The Company is headquartered near Oxford, U.K. and in Marlborough, MA.